Articles tagged with: Bortezomib
Results from a retrospective Canadian study indicate that combination therapy with Revlimid, Velcade, and dexamethasone is effective for certain heavily pretreated multiple myeloma patients. The findings show that nearly 50 percent of patients with advanced myeloma respond to the three-drug therapy.
The study investigators point out that although most patients with advanced myeloma progress quickly after therapy with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), particularly those with high-risk myeloma, some patients experience a “considerable benefit.”
They also note that side effects in this heavily pretreated patient …
Results from a Spanish Phase 3 clinical trial suggest that initial treatment with a combination of Velcade, thalidomide, and dexamethasone may lead to better responses before and after stem cell transplantation, as compared to treatment with thalidomide and dexamethasone alone. In addition, treatment with the three-drug combination increases progression-free survival time.
The study investigators concluded that their findings support the use of a combination of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), often referred to as VTD, as initial treatment in newly diagnosed myeloma patients who are …
Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus prednisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.
In addition, elderly myeloma patients who receive Velcade plus thalidomide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus prednisone as maintenance therapy.
“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the differences didn’t …
ALT-801 Phase 1/2 Clinical Trial Is Enrolling Relapsed Or Refractory Myeloma Patients – The Florida-based biopharmaceutical company Altor Bioscience has started a Phase 1/2 clinical trial of its investigational drug ALT-801. The trial is being conducted at the University of Iowa and is recruiting myeloma patients who have had at least two previous treatment regimens. ALT-801 is a protein that triggers immune cells to attack cancer cells. The drug also is being explored as a potential treatment for melanoma and bladder cancer. For more information, see the clinical trial description and information about ALT-801 at the Altor website.
Study Supports Use Of Once-Weekly Velcade – Results from a recent retrospective Chinese study support previous findings that once-weekly Velcade (bortezomib) is similar to twice-weekly Velcade in terms of efficacy and safety. Similar results were first found in 2010 during a study of Velcade in combination with melphalan (Alkeran), prednisone, and thalidomide (Thalomid). The results from that study showed that once-weekly Velcade was as effective as twice-weekly Velcade and that patients who received Velcade once a week experienced fewer side effects, especially peripheral neuropathy (pain, tingling, or loss of sensation in the extremities), a common side effect of Velcade (see related Beacon news). The current study found that overall response rates were similar for patients treated with once-weekly (77 percent) or twice-weekly Velcade (75 percent) in combination with dexamethasone (Decadron). In addition, the median progression-free survival was similar in both groups (8 months versus 10 months, respectively). Side effects were more common among patients treated twice a week; however, the differences were not statistically significant. In particular, 31 percent of patients treated with once-weekly Velcade developed neuropathy as compared to 50 percent of patients treated with twice-weekly Velcade. For more information, please see the study in the Journal of Huazhong University of Science and Technology (abstract).
Age And Platelet Count May Predict Ability To Collect Enough Stem Cells For Transplant – Findings from a recent study show that age and platelet count can be used to predict whether a multiple myeloma patient is likely to successfully harvest enough stem cells for a transplant. Patients older than 58 years or who had a baseline platelet count less than 161,000 cells/mm3 failed to collect enough stem cells using granulocyte colony-stimulating factor (G-CSF) to mobilize the stem cells into the blood for collection. The study investigators conclude that patients with these characteristics should not receive mobilization with G-CSF alone and that alternative methods of mobilization should be tested. For more information, please see the study in Transfusion and Apheresis Science (abstract).
Treatment-Free Intervals Improve Quality Of Life For Multiple Myeloma Patients – A recent survey of multiple myeloma patients in the United Kingdom shows that patients in their first treatment-free interval and those experiencing a longer treatment-free interval enjoy better quality of life as compared to patients in other phases of treatment. The investigators believe these results may help doctors and patients make treatment decisions, especially when considering extended treatment plans. For more information, please refer to the study in Supportive Care in Cancer (abstract).
Phase 1 Trial Of All-Oral Rocilinostat-Revlimid-Dexamethasone Combo Begins – Acetylon Pharmaceuticals announced last week the initiation of a Phase 1b clinical trial of rocilinostat (ACY-1215) in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) for the treatment of patients with relapsed or refractory multiple myeloma. Rocilinostat is an oral treatment that belongs to a family of anti-cancer drugs called HDAC inhibitors. Other HDAC inhibitors under investigation for multiple myeloma include Zolinza (vorinostat) and panobinostat. Acetylon believes that rocilinostat could produce fewer side effects than other non-specific HDAC inhibitors, as it selectively inhibits the enzyme HDAC6. The primary aim of the trial is to establish an optimal dose of rocilinostat over a 28-day treatment cycle and to assess the potential anti-myeloma activity of the three-drug combination. In addition, Acetylon is enrolling patients for a Phase 1/2 trial of rocilinostat in combination with Velcade (bortezomib) and dexamethasone in patients with relapsed or refractory myeloma. For more information on both trials, please see the Acetylon press release and the U.S. clinical trial registry.
Lucatumumab Shows Modest Activity As Single Agent In Relapsed/Refractory Myeloma – Results from a recent Phase 1 study indicate that lucatumumab, an antibody developed by Novartis, is well tolerated in relapsed or refractory myeloma patients; however, the compound only showed modest activity in the study participants. Specifically, 4 percent of patients maintained a partial response for a period of eight months or longer, and 43 percent maintained stable disease. The most common severe side effects included anemia (7 percent), chills (7 percent), and fever (7 percent). Side effects severe enough to limit drug dosage were seen in about 10 percent of patients. Based on these results, the researchers recommend that lucatumumab be tested in combination with other anti-myeloma drugs. For more information, please see the study in the British Journal of Hematology (abstract).
Viracept-Velcade Combo Kills Myeloma Cells Better Than Either Drug Alone – Researchers at the National Cancer Institute have found that a combination of the anti-HIV drug Viracept (nelfinavir) and Velcade kills myeloma cells better than either drug alone in a preclinical study. Viracept belongs to a class of drugs called protease inhibitors and was approved by the FDA to treat HIV in 1997. Both Viracept and Velcade limit a cell’s ability to chop up and discard unwanted proteins. Simultaneous treatment with both drugs resulted in an accumulation of such unwanted proteins in the cell, eventually resulting in cell death. For more information, please refer to the study in Cell Death and Disease.